BVI announced the first US implantations of its FDA-approved Finevision HP hydrophobic trifocal IOL. The milestone follows the product’s FDA approval in October 2025.

The initial procedures were performed by five leading cataract and refractive surgeons, all members of BVI’s U.S. Surgical Leadership Council, at multiple surgical centers across the country:

  • George O. Waring IV, MD, Ladson, SC

  • Nathan M. Radcliffe, MD, Bronx, NY

  • Nicole Fram, MD, Beverly Hills, CA

  • Robert J. Weinstock, MD, Largo, FL

  • Vance Thompson, MD, Sioux Falls, SD

The Finevision HP was developed through a collaboration between BVI R&D Director Christophe Pagnoulle and ophthalmologist Damien Gatinel, MD, PhD, and has been widely used globally a strong body of supporting evidence.

The third-generation Finevision HP incorporates BVI’s proprietary POD platform and CoPODize technology. The design is engineered to balance and harmonize light distribution across distance, intermediate, and near focal points while minimizing visual disturbances. In addition, its double C-loop haptic design provides four points of in-the-bag contact and a 120-degree contact angle, offering enhanced stability compared with conventional C-loop configurations.

US clinical evaluation, supported by extensive global evidence, has demonstrated strong contrast sensitivity, stable visual performance across a wide range of lighting conditions, enhanced near vision in dim light, and a smooth, continuous range of vision from far to near, according to BVI.

“As a third-generation design, Finevision HP reflects the latest advances in presbyopia-correcting IOL technology, incorporating an optical platform refined over time to meet the evolving expectations of today’s premium cataract surgeons,” said Andy Chang, Chief Commercial Officer of BVI. “This milestone marks the moment when a category-defining trifocal platform—backed by more than 15 years of global clinical use and demonstrated outcomes—officially enters U.S. surgical practice. We are deeply grateful to the pioneering surgeons who performed these first U.S. implantations, as well as to the BVI teams whose expertise and commitment have supported this disciplined, surgeon-led rollout.”

BVI said it is methodically rolling out Finevision HP across select US centers, with a focus on surgeon training, phased availability, and real-world performance validation. Broader access is expected to expand nationwide throughout 2026 as manufacturing capacity increases and surgeon onboarding progresses.